Analytical Data
-
Gene name
CDHE
- Application
-
Alternative Names
CDHE；CDHE；UVO；；Cadherin-1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P12830
-
Expression Region
155-707aa
-
AA Sequence
DWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGV FIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTD QNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTI LSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEG LSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAP NTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHV AVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQE ITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFE HVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCE RNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKP KMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAG LQI
-
Molecular Weight
64 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of recombinant CDHE (C-terminal domain of the human Epidermal Growth Factor Receptor) proteins has gained significant attention due to their potential implications in cancer therapy and cellular signaling regulation. CDHE plays a crucial role in the activation and dimerization of the EGF receptor, which is implicated in various malignancies, including breast and lung cancer. Understanding its structure and function can provide insights into the mechanisms of signal transduction pathways that govern cell proliferation, survival, and differentiation. Researchers have focused on developing recombinant CDHE proteins to explore their interactions with other cellular components and to assess their utility as therapeutic targets or biomarkers for disease progression. The advent of recombinant DNA technology has facilitated the efficient production of these proteins in various expression systems, enabling detailed functional studies and high-throughput screening for potential inhibitors. Furthermore, the structural elucidation of CDHE through techniques like X-ray crystallography and NMR has opened new avenues for rational drug design, targeting the EGF receptor's aberrant signaling in cancer cells. This research is vital not only for developing innovative cancer therapies but also for enhancing our understanding of fundamental biological processes mediated by receptor tyrosine kinases.
